Loading...
XJPX2784
Market cap2.53bUSD
Dec 25, Last price  
2,128.50JPY
1D
-0.88%
1Q
-9.54%
Jan 2017
10.06%
Name

Alfresa Holdings Corp

Chart & Performance

D1W1MN
XJPX:2784 chart
P/E
13.46
P/S
0.14
EPS
158.15
Div Yield, %
3.08%
Shrs. gr., 5y
-2.08%
Rev. gr., 5y
1.60%
Revenues
2.86t
+6.02%
1,411,691,000,0001,589,881,000,0001,769,384,000,0001,934,893,000,0002,059,328,000,0002,183,356,000,0002,333,465,000,0002,387,435,000,0002,504,574,000,0002,421,105,000,0002,576,360,000,0002,551,919,000,0002,602,925,000,0002,640,529,000,0002,698,555,000,0002,603,263,000,0002,585,643,000,0002,696,069,000,0002,858,500,000,000
Net income
29.56b
+14.63%
7,073,000,00011,941,000,00016,177,000,0005,565,000,00010,497,000,0006,587,000,0006,604,000,00020,771,000,00025,566,000,00022,922,000,00034,975,000,00030,893,000,00035,589,000,00041,699,000,00040,273,000,00024,501,000,00032,182,000,00025,786,000,00029,558,000,000
CFO
86.38b
+560.09%
24,665,000,00039,993,000,000-8,246,000,00032,963,000,0006,898,000,00052,233,000,00014,620,000,00082,339,000,000-27,507,000,00035,813,000,00037,836,000,00034,342,000,00047,575,000,00046,880,000,00033,828,000,000-21,191,000,00036,546,000,00013,086,000,00086,379,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 06, 2025

Profile

Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is involved in the ethical pharmaceuticals wholesaling business that offers diagnostic reagents and medical devices/equipment to hospitals, clinics, and dispensing pharmacies. The company also engages in self-medication products wholesaling business that offers over-the-counter drugs, including health foods, supplements, and other products to drug stores and pharmacies. In addition, it manufactures and markets active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices, as well as undertakes contract manufacturing of pharmaceuticals. Further, the company's medical-related business includes its dispensing pharmacy and other medical-related activities. Alfresa Holdings Corporation was incorporated in 2003 and is based in Tokyo, Japan.
URL
https://www.alfresa.com/
IPO date
Sep 29, 2003
Employees
11,772
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
2,858,500,000
6.02%
2,696,069,000
4.27%
2,585,643,000
-0.68%
Cost of revenue
2,812,228,000
2,658,184,000
2,548,763,000
Unusual Expense (Income)
NOPBT
46,272,000
37,885,000
36,880,000
NOPBT Margin
1.62%
1.41%
1.43%
Operating Taxes
14,221,000
12,802,000
15,977,000
Tax Rate
30.73%
33.79%
43.32%
NOPAT
32,051,000
25,083,000
20,903,000
Net income
29,558,000
14.63%
25,786,000
-19.87%
32,182,000
31.35%
Dividends
(12,245,000)
(11,138,000)
(11,430,000)
Dividend yield
2.87%
3.25%
3.21%
Proceeds from repurchase of equity
(35,726,000)
(1,731,000)
(17,139,000)
BB yield
8.38%
0.50%
4.81%
Debt
Debt current
1,565,000
1,394,000
1,795,000
Long-term debt
38,309,000
6,316,000
8,235,000
Deferred revenue
6,000
9,580,000
13,065,000
Other long-term liabilities
10,448,000
1,262,000
987,000
Net debt
(281,777,000)
(260,320,000)
(274,277,000)
Cash flow
Cash from operating activities
86,379,000
13,086,000
36,546,000
CAPEX
(15,719,000)
(25,465,000)
(16,988,000)
Cash from investing activities
(14,217,000)
(20,539,000)
2,304,000
Cash from financing activities
(19,698,000)
(12,918,000)
(29,151,000)
FCF
67,324,000
(4,030,000)
22,228,000
Balance
Cash
213,756,000
160,122,000
180,436,000
Long term investments
107,895,000
107,908,000
103,871,000
Excess cash
178,726,000
133,226,550
155,024,850
Stockholders' equity
458,550,000
873,437,000
842,301,000
Invested Capital
346,517,000
363,758,450
324,976,150
ROIC
9.02%
7.28%
6.45%
ROCE
8.53%
7.44%
7.50%
EV
Common stock shares outstanding
191,777
202,368
209,558
Price
2,222.50
31.04%
1,696.00
-0.18%
1,699.00
-20.35%
Market cap
426,224,382
24.19%
343,216,128
-3.60%
356,039,042
-21.14%
EV
144,706,382
525,277,128
509,507,042
EBITDA
59,786,000
51,187,000
49,704,000
EV/EBITDA
2.42
10.26
10.25
Interest
132,000
64,000
73,000
Interest/NOPBT
0.29%
0.17%
0.20%